Specific humoral immune response to the Thomsen-Friedenreich tumor antigen (CD176) in mice after vaccination with the commensal bacterium Bacteroides ovatus D-6

Cancer Immunology, Immunotherapy

Volumn 62, Issue 5, 2013, Pages 875-887

  Ulsemer, Philippe ^a   Henderson, Gemma ^b,c   Toutounian, Kawe ^a   Löffler, Anja ^a   Schmidt, Jens ^a   Karsten, Uwe ^a   Blaut, Michael ^b   Goletz, Steffen ^a  

^a GLYCOTOPE GMBH   (Germany)

^b GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^c AGRESEARCH GRASSLANDS   (New Zealand)

Author keywords

Bacteroides ovatus; Cancer; Commensal bacteria; Immune response; Thomsen Friedenreich antigen; Vaccine

Indexed keywords

CANCER VACCINE; CD176 ANTIGEN; EPITOPE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; IMMUNOLOGICAL ADJUVANT; INACTIVATED VACCINE; LYMPHOCYTE ANTIGEN; THOMSEN FRIEDENREICH TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN ANTIBODY COMPLEX; ANTIGEN EXPRESSION; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTEROIDES OVATUS; BIOLOGICAL ACTIVITY; BLOOD ANALYSIS; CONTROLLED STUDY; DRUG FORMULATION; EPITOPE MAPPING; FEMALE; HUMORAL IMMUNITY; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINATION;

ANIMALS; ANTIGENS, NEOPLASM; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; BACTEROIDES; CANCER VACCINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; FEMALE; GASTROINTESTINAL TRACT; GENE EXPRESSION REGULATION, BACTERIAL; HUMANS; IMMUNITY, HUMORAL; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFUSIONS, PARENTERAL; MICE; MICE, INBRED C3H; STOMACH;

EID: 84877818981     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-013-1394-x     Document Type: Article

References (45)

1. Cao Y, Karsten UR, Liebrich W, Haensch W, Springer GF, Schlag PM (1995) Expression of Thomsen-Friedenreich-related antigens in primary and metastatic colorectal carcinomas. A reevaluation. Cancer 76:1700-1708
2. Cao Y, Stosiek P, Springer GF, Karsten U (1996) Thomsen-Friedenreich- related carbohydrate antigens in normal adult human tissues: a systematic and comparative study. Histochem Cell Biol 106:197-207
3. Goletz S, Cao Y, Danielczyk A, Ravn P, Schoeber U, Karsten U (2003) Thomsen-Friedenreich antigen: the "hidden" tumor antigen. Adv Exp Med Biol 535:147-162
4. Irazoqui FJ, Jansson B, Lopez PH, Nores GA (2001) Correlative fine specificity of several Thomsen-Friedenreich disaccharide-binding proteins with an effect on tumor cell proliferation. J Biochem 130:33-37
5. Kurtenkov O, Klaamas K, Mensdorff-Pouilly S, Miljukhina L, Shljapnikova L, Chuzmarov V (2007) Humoral immune response to MUC1 and to the Thomsen-Friedenreich (TF) glycotope in patients with gastric cancer: relation to survival. Acta Oncol 46:316-323
6. Shigeoka H, Karsten U, Okuno K, Yasutomi M (1999) Inhibition of liver metastases from neuraminidase-treated colon 26 cells by an anti-Thomsen- Friedenreich-specific monoclonal antibody. Tumor Biol 20:139-146
7. Springer GF (1984) T and Tn, general carcinoma autoantigens. Science 224:1198-1206
8. Yu LG (2007) The oncofetal Thomsen-Friedenreich carbohydrate antigen in cancer progression. Glycoconj J 224:411-420
9. Zhang S, Zhang HS, Cordon-Cardo C, Reuter VE, Singhal AK, Lloyd KO et al (1997) Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group-related antigens. Int J Cancer 73:50-56
10. Springer GF (1997) Immunoreactive T and Tn epitopes in cancer diagnosis, prognosis, and immunotherapy. J Mol Med 75:594-602
11. MacLean GD, Bowen-Yacyshyn MB, Samuel J, Meikle A, Stuart G, Nation J et al (1992) Active immunization of human ovarian cancer patients against a common carcinoma (Thomsen-Friedenreich) determinant using a synthetic carbohydrate antigen. J Immunother 11:292-305
12. Adluri S, Helling F, Ogata S, Zhang S, Itzkowitz SH, Lloyd KO et al (1995) Immunogenicity of synthetic TF-KLH (keyhole limpet hemocyanin) and sTn-KLH conjugates in colorectal carcinoma patients. Cancer Immunol Immunother 41:185-192
13. Slovin SF, Ragupathi G, Musselli C, Fernandez C, Diani M, Verbel D et al (2005) Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer. Cancer Immunol Immunother 54:694-702
14. Irazoqui FJ, Lopez PHH, Vides MA, Nores GA (2000) Novel immunogenicity of Thomsen-Friedenreich disaccharide obtained by a molecular rotation on its carrier linkage. Glycobiology 10:781-787
15. Xu Y, Gendler SJ, Franco A (2004) Designer glycopeptides for cytotoxic T cell-based elimination of carcinomas. J Exp Med 199:707-716
16. Heimburg-Molinaro J, Almogren A, Morey S, Glinskii OV, Roy R, Wilding GE et al (2009) Development, characterization, and immunotherapeutic use of peptide mimics of the Thomsen-Friedenreich carbohydrate antigen. Neoplasia 11:780-792
17. Brinas RP, Sundgren A, Sahoo P, Morey SM, Rittenhouse-Olson K, Wilding GE et al (2012) Design and synthesis of multifunctional gold nanoparticles bearing tumor-associated glycopeptide antigens as potential cancer vaccines. Bioconjug Chem 23:1513-1523
18. Hoffmann-Röder A, Kaiser A, Wagner S, Gaidzik N, Kowalczyk D, Westerlind U et al (2010) Synthetic antitumor vaccines from tetanus toxoid conjugates of MUC1 glycopeptides with the Thomsen-Friedenreich antigen and a fluorine-substituted analogue. Angew Chem Int Ed 49:8498-8503
19. 3CysSer. Angew Chem Int Ed 50:1635-1639
20. Cai H, Huang Z-H, Shi L, Sun Z-Y, Zhao Y-F, Kunz H, Li Y-M (2012) Variation of the glycosylation pattern in MUC1 glycopeptide BSA vaccines and its influence on the immune response. Angew Chem Int Ed 51:1719-1723
21. Springer GF, Desai PR, Murthy MS, Scanlon EF (1979) Human carcinoma-associated precursor antigens of the NM blood group system. J Surg Oncol 11:95-106
22. Butschak G, Karsten U (2002) Isolation and characterization of Thomsen-Friedenreich-specific antibodies from human serum. Tumor Biol 23:113-122
23. Boccardi V, Attina D, Girelli G (1974) Influence of orally administered antibiotics on anti-T agglutinin of normal subjects and of cirrhotic patients. Vox Sang 27:268-272
24. Springer GF, Tegtmeyer H (1981) Origin of anti-Thomsen-Friedenreich (T) and Tn agglutinins in man and in White Leghorn chicks. Br J Haematol 47:453-460
25. Klaamas K, Kurtenkov O, Rittenhouse-Olson K, Brjalin V, Miljukhina L, Shljapnikova L et al (2002) Expression of tumor-associated Thomsen-Friedenreich antigen (T Ag) in Helicobacter pylori and modulation of T Ag specific immune response in infected individuals. Immunol Invest 31:191-204
26. Thors C, Jansson B, Helin H, Linder E (2006) Thomsen-Friedenreich oncofetal antigen in Schistosoma mansoni: localization and immunogenicity in experimental mouse infection. Parasitology 132:73-81
27. Gilboa-Garber N, Sudakevitz D (2001) Usage of Aplysia lectin interactions with T antigen and poly-N-acetyllactosamine for screening of E. coli strains which bear glycoforms cross-reacting with cancer-associated antigens. FEMS Immunol Med Microbiol 30:235-240
28. Henderson G, Ulsemer P, Schöber U, Löffler A, Alpert CA, Zimmermann-Kordmann M et al (2011) Occurrence of the human tumor-specific antigen structure Galß1-3GalNAc{alpha}- (Thomsen-Friedenreich) and related structures on gut bacteria: prevalence, immunochemical analysis and structural confirmation. Glycobiology 21:1277-1289
29. Smorodin EP, Kurtenkov OA, Sergeyev BL, Kodar KE, Chuzmarov VI, Afanasyev VP (2008) Postoperative change of anti-Thomsen-Friedenreich and Tn IgG level: the follow-up study of gastrointestinal cancer patients. World J Gastroenterol 14:4352-4358
30. Zhou ZH, Tzioufas AG, Notkins AL (2007) Properties and function of polyreactive antibodies and polyreactive antigen-binding B cells. J Autoimmun 29:219-228
31. Ehrenstein MR, Notley CA (2010) The importance of natural IgM: scavenger, protector and regulator. Nat Rev Immunol 10:778-786
32. Jones HE, Taylor PR, McGreal E, Zamze S, Wong SY (2009) The contribution of naturally occurring IgM antibodies, IgM cross-reactivity and complement dependency in murine humoral responses to pneumococcal capsular polysaccharides. Vaccine 27:5806-5815
33. Racine R, Winslow GM (2009) IgM in microbial infections: taken for granted? Immunol Lett 125:79-85
34. Bundle DR (2007) A carbohydrate vaccine exceeds the sum of its parts. Nat Chem Biol 3:605-606
35. Dintzis RZ, Okajima M, Middleton MH, Greene G, Dintzis HM (1989) The immunogenicity of soluble haptenated polymers is determined by molecular mass and hapten valence. J Immunol 143:1239-1244
36. Stein KE (1992) Thymus-independent and thymus-dependent responses to polysaccharide antigens. J Infect Dis 165:49-52
37. Mond JJ, Lees A, Snapper CM (1995) T cell-independent antigens type 2. Annu Rev Immunol 13:655-692
38. Lucas AH, Apicella MA, Taylor CE (2005) Carbohydrate moieties as vaccine candidates. Clin Infect Dis 41:705-712
39. Lucas AH, Moulton KD, Tang VR, Reason DC (2001) Combinatorial library cloning of human antibodies to Streptococcus pneumoniae capsular polysaccharides: variable region primary structures and evidence for somatic mutation of Fab fragments specific for capsular serotypes 6B, 14, and 23F. Infect Immun 69:853-864
40. Zhou J, Lottenbach KR, Barenkamp SJ, Lucas AH, Reason DC (2002) Recurrent variable region gene usage and somatic mutation in the human antibody response to the capsular polysaccharide of Streptococcus pneumoniae type 23F. Infect Immun 70:4083-4091
41. Swanson CL, Wilson TJ, Strauch P, Colonna M, Pelanda R, Torres RM (2010) Type I IFN enhances follicular B cell contribution to the T cell-independent antibody response. J Exp Med 207:1485-1500
42. Slovin SF, Ragupathi G, Adluri S, Ungers G, Terry K, Kim S et al (1999) Carbohydrate vaccines in cancer: immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man. Proc Natl Acad Sci 96:5710-5715
43. Koeffler HP, Golde DW (1978) Acute myelogenous leukemia: a human cell line responsive to colony-stimulating activity. Science 200:1153-1154
44. Paetz A (2000) Neue DIN 19738: 2000-05 (Entwurf): soil quality - Absorption availability of organic and inorganic pollutants from contaminated soil material. Umweltmedizin in Forschung und Praxis 5:319-320
45. Chapman PB, Morrissey DM, Panageas KS, Hamilton WB, Zhan C, Destro AN et al (2000) Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet 701 hemocyanin + QS21 vaccine: a dose-response study. Clin Cancer Res 6:874-879